CCIC 2019 Annual Meeting Overview

DATE: SEPTEMBER 18-20, 2019
​LOCATION: Ben Sadowski Auditorium, Mount Sinai Hospital
600 University Avenue (18th Floor), Toronto, Ontario, Canada 

Immunotherapy has revolutionized the treatment of cancer, as PD-1 blockade and CAR-T cell therapies are becoming the standard of care in many disease settings.  However the field needs to learn much more about the basic biology of immunoregulation as well as the response and resistance mechanisms in patients to bring this to the next level.  Several topics that will be highlighted include:
  • Strategies to improve anti-tumor immunity
  • Insights into immunoregulation
  • Novel cell subsets
  • Autoimmunity as a consequence of PD-1 blockade
  • Insights from clinical trials​
KEYNOTE SPEAKERS
​
Tasuku Honjo - Kyoto University, Japan, Nobel Prize in Physiology or Medicine 2018 recipient
Jan Joseph Melenhorst - University of Pennsylvania, US
Jedd D. Wolchok - Memorial Sloan Kettering Cancer Center, US​
2019 CCIC PROGRAM OVERVIEW
​The 12th Annual CCIC Symposium - Sept 18-20, 2019 (Mt Sinai Hospital, Toronto)
​Wednesday, Sept 18

13:00 – 15:00
14:30 – 15:00 

15:00 – 16:30 





​16:30 – 18:30


​Thursday, Sept 19
​
08:00 – 08:30
​
08:30 – 10:00


​

​
​
10:00 – 10:30

10:30 – 12:00






12:00 – 14:00

14:00 – 15:30





​
15:30 – 16:00

16:00 – 17:00


​
18:00 – 20:00

Friday, Sept 20
​
08:00 – 08:30
​
08:30 – 10:00






10:00 – 10:30

10:30 – 11:00



​
11:00 – 12:00

​

12:00 – 12:15


12:15


​Registration (Mt Sinai 18th floor, auditorium lobby)
Coffee (Mt Sinai 18th floor, auditorium lobby)

Opening remarks (Mt Sinai 18th floor, auditorium), Jonathan Bramson (McMaster University)
Opening Keynote: Chair: Jonathan Bramson (McMaster University)
Joseph Melenhorst (University of Pennsylvania, CAR T Cell Manufacturing: A Continued Cycle Between The Bench and Bedside
Speed poster session 1 (oral presentations)
​
​Opening night reception (Princess Margaret, 7th floor atrium)
Poster session 1 and networking | Browse sponsor exhibits


​
Registration, breakfast and networking (Mt Sinai 18th floor, auditorium lobby)

​Session 1: Modulating Immunity and anti-tumor immunity (Mt Sinai 18th floor, auditorium)
Chair: Marie-Claude Bourgeois-Daigneaut (CHUM)
Sergio Quezada (University College London), Targeting Regulation Within Tumours: From Mechanisms to New Therapies
Marie-Claude Bourgeois-Daigneaut (CHUM), Oncolytic viruses for personalized anti-cancer vaccination
Speed poster session 2 (oral presentations)

Coffee (Mt Sinai 18th floor auditorium lobby)

Session 2: Modulating clinical outcomes (Mt Sinai 18th floor auditorium), Chair: Marie-Claude Bourgeois-Daigneaut (CHUM)
Joan Seoane (Vall d’Hebron University Hosptial), The immunosuppressive role of LIF in cancer
Tania Watts (University of Toronto), Targeting the PKN1- TRAF1 signaling axis to overcome venetoclax resistance in B- CLL
Jen Gommerman (University of Toronto), B cells in Multiple Sclerosis - Friend or Foe?

Lunch and networking (Princess Margaret 7th floor atrium) Browse sponsor exhibits

Session 3: Understanding responses and the tumor microenvironment (Mr Sinai 18th floor aditorium)
Chair: Pam Ohashi (Princess Margaret Cancer Centre)
Jen Wargo (MD Anderson), The role of the microbiome in cancer
Michael Angelo (Stanford University), Comprehensive enumeration of immune cells in clinical tissue biopsies using MIBI
Short talks – session 1

Coffee (Mt Sinai 18th floor audotorium lobby)

Keynote Lecture (Mt Sinai 18th floor auditorium)
Chair: Pam Ohashi (Princess Margatet Cancer Centre)
Tasuku Honjo (Kyoto University) Serendipities of acquired immunity

Conference dinner (Doubletree by Hilton, 108, Chestnut Street, Toronto)



​Breakfast (Mt Sinai 18th floor auditorium lobby)

Session 4: PD-1 blockade – trials and consequences (Mt Sinai 18th floor auditorium)
Chair: Rejean Lapointe (University of Montreal)
Kevin Herold (Yale University), Mechanisms of autoimmune diabetes induced by checkpoint inhibitors
Javid Moslehi (Vanderbilt University), Immune checkpoint inhibitor-associated cardiotoxicities: Learning from mice and humans
Short talks – session 2

Coffee break (Mt Sinai 18th floor audotorium lobby)

Session 5: PD-1 blockade – trails and consequences (continued) (Mt Sinai 18th floor auditorium)
Chair: Rejean Lapointe (Unviersity of Montreal)
Dario Vignali (University of Pittsburgh), Resistance Mechanisms that Limit the Efficacy of Cancer Immunotherapy

Closing Keynote Lecture, Chair: Rejean Lapointe (Princess Margaret Cancer Centre)
Jedd Wolchok (Memorial Sloan Kettering Cancer Center), Immune-Modulating Approaches to Cancer Therapy: Focusing on Combinations

Poster awards: Lee-Hwa Tai
Closing remarks: Pam Ohashi (Princess Margaret Cancer Centre)

Meeting close
2018 CCIC PROGRAM OVERVIEW
​The 11th Annual CCIC Symposium - June 18-20, 2018 (Pinnacle Hotel at the Pier, North Vancouver), Joint CCIC-ImmunoBC meetin​g
Monday, June 18

07:30 - 08:20
​
08:20-08:30
​
08:30-10:00


​


​

​10:00-10:30






​
10:30-11:00
​
11:00-12:00






12:00-12:30

​
12:30-13:30

13:30-15:00

15:00-16:00




16:00-16:30




16:30-17:00

17:00-18:00


​
​18:00-19:00
19:00-21:00

​
Tuesday, June 19

​07:30-08:20

08:20-08:30

08:30-10:00







10:00-10:30




10:30-11:00

11:00-12:00



​
12:00-12:30


12:30-13:30

13:30-15:00


15:00-16:00





16:00-16:30





16:30-17:00

17:00-18:00




18:00-18:30

18:30-20:30

​
Registration, Coffee and Poster Set-up
​
Day 1 Welcome - Brad Nelson

Session 1: Engineered T cells in the clinic
​Chair: Brad Nelson. BC Cancer- Deeley Research Centre
Keynote Speaker- Stanley Riddell, Fred Hutchinson Cancer Research Centre, "Improving the efficacy and safety of genetically modified T cells for cancer therapy"

Advances in T cell engineering (Part 1) Chair Brad Nelson Richard Morgan, Bluebird Bio
"Developing the next generation of CAR and TCR engineered T cells for solid tumor applications"

Trainee Talks: Session 1, Chair: Brad Nelson, BC Cancer, Deeley Centre
Israel Matos, University of British Columbia
"Systems level mass cytometry reveals that tumour-derived G-CSF induces immunosuppression and poses a barrier to immunotherapy".
Tim Guo, Princess Margaret Cancer Centre
"Engineering Mesothelin-Specific T Cells using a Chimeric Antigen Receptor Delivering JAK-STAT signals"

Morning Break

Session 2: Advances in T cell engineering 
Chair: Etienne Gagnon, Univ. Montréal
David Rawlings, Seattle Children's Hospital, "Efficient genetic engineering of human immune cells for novel clinical applications"
Jonathan Bramson, McMaster University, "The T cell antigen coupler (TAC) receptor is a novel chimeric receptor that re-directs the endogenous TCR"

Speed poster session 1
​Chair: Etienne Gagnon, Univ. Montréal

Lunch

Poster session 1, See poster assignments

Session 3: Advances in TIL therapy
​Chair: Jonathan Bramson, McMaster University
Eric Tran, Providence, Portland, "Targeting cancer neoantigens with adoptive T-cell therapy”
Christian Hinrichs, NIH/NCI, "Adoptive T-cell therapy for epithelial cancers”

Trainee Talks: Session 2, Chair: Jonathan Bramson, McMaster University
John Edgar, University of Toronto
"Progenitor T-cell differentiation from stem cells for adoptive cell immunotherapies"
Diana Canals Hernaez, University of British Columbia "Podocalyxin is a therapeutic target in carcinoma”

Afternoon Break

Keynote Lecture - David Raulet, UC Berkeley
Chair: Jeanette Boudreau
"NK cell activation and Inhibition: Potential applications to cancer therapy”

Evening Reception
Dinner



​
​Coffee, Muffins and Poster set-up
​
Day 2 Welcome - Rob Holt, BC Cancer

Session 4: Amplifying Natural Killer cell responses
Chair: Rob Holt, BC Cancer
Todd Fehniger, Washington University, "Translating NK cell memory into cancer immunotherapy"
Jeanette Boudreau, Dalhousie University, "Leveraging immunogenetic diversity among natural killer cells for precise cancer therapy"
Michele Ardolino, University of Ottawa, "The checkpoint receptor PD-1 inhibits NK cell activity against cancer"

Trainee Talks: Session 3, Chair: Rob Holt, BC Cancer
Matthew Gynn, University of British Columbia, "The effect of pathogenic vs. nonpathogenic early life exposures on acute lymphoblastic leukemia progression in Em-RET mice"
Haider AL-Janabi, Sheffield University, "Breast Cancer immunotherapy using magnetised HSV1716"

Morning break

Session 5: Genomic Approaches to Personalized Immunotherapy
Chair: Julian Lum, BC Cancer
Els Verdegaal, Leiden University Medical Centre "Neoantigen landscape dynamics during T cell therapy"
Karl Peggs, University College London "Gene-edited cell therapies"

Speed poster session 2
​Chair: Julian Lum, BC Cancer

Lunch

Poster session 2
​See poster assignments

Session 6: Cell engineering in the Canadian landscape
Chair: Jonathan Choy, SFU
Tania Bubela, Simon Fraser University, "Regulatory and intellectual property interests for cell therapies and manufacture"
Peter Zandstra, University of British Columbia “Engineering blood development and therapies"
​
Trainee Talks: Session 4
Elizabeth Franks, BC Cancer, "Oncogenic drivers of lung cancer induce production of CCL5 to recruit regulatory T cells during early tumour development"
Maartje Wouters, BC Cancer, "Landscape of tumor-infiltrating lymphocytes across metastatic sites at the time of death from ovarian cancer"

Afternoon Break and ImmunoBC Registration Opens

Joint Keynote Lecture - Mark Davis, Stanford University
Chair: Pam Ohashi, Princess Margaret Cancer Centre
"Tools for T cells: characterizing the T cell response repertoire in cancer, autoimmunity and infectious diseases"

CCIC Poster and Talk Awards.

Immuno BC Trainee Workshop Session - Career Advice

DOWNLOAD PAST CCIC PROGRAMS

CCIC Annual Symposiums - Annual CCIC meeting celebrates excellence in cancer immunotherapy research and provides a platform for investigator of all levels and trainees to further accelerate their research and career. 

CANADIAN CANCER IMMUNOTHERAPY CONSORTIUM